Back to search
FDAFDA · Food and drugs·Recall number D-1470-2016

Amoxicillin for Oral Suspension USP, 400 mg/ 5 mL, 50 mL bottle, Rx only, Manufactured In Canada by: Teva Canada Limited, Toronto, Canada, NDC 0093-4161-76

Published August 31, 2016 · Recall initiated: June 24, 2016

Summary

FDA records drug Class II recall D-1470-2016, published August 31, 2016 and initiated June 24, 2016. Recalling firm: Teva North America; Status: Terminated; Reported quantity: 53,328 bottles; Lot: Lot # 35434158A, Exp 6/17. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Superpotent drug: Out of specification test result for assay during stability testing.

What to do

Voluntary: Firm initiated · Letter

Get an email if AMOXICILLIN has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
AMOXICILLIN
Manufacturer
Teva North America
Distributor
Nationwide
UPC
0300933107051
Lot
Lot # 35434158A, Exp 6/17
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Amoxicillin for Oral Suspension USP, 400 mg/ 5 mL, 50 mL bottle, Rx only, Manufactured In Canada by: Teva Canada Limited, Toronto, Canada, NDC 0093-4161-76 recalled?

Yes. FDA published recall D-1470-2016 on August 31, 2016. Reported hazard: Superpotent drug: Out of specification test result for assay during stability testing.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: AMOXICILLIN. UPC: 0300933107051.